- Sanofi and MyoKardia are teaming up to develop therapies for patients with genetic cardiomyopathies, including hypertrophic cardiomyopathy and dilated cardiomyopathy.
- The deal is worth $200 million in equity investments, milestone payments, and R&D services through 2018.
- As part of the deal, Sanofi has taken in an undisclosed stake in MyoKardia, a US-based and privately held company.
Sanofi has a strategic partnership model called the Sunrise Initiative. This initiative provides a foundation for investing in early-stage opportunities, such as the venture with MyoKardia.
Myokardia was founded in 2012 and funded by Third Rock Ventures. As the proposed deal progresses, Sanofi and Myokardia will share development costs of the hypertrophic cardiomyopathy program, while Sanofi alone will pay for the dilated cardiomyopathy program.